A New Class of
<i>C</i>
<sub>2</sub>
‐Symmetric Chiral Cyclopentadienyl Ligand Derived from Ferrocene Scaffold: Design, Synthesis and Application
作者:Hao Liang、Laxmaiah Vasamsetty、Teng Li、Jijun Jiang、Xingying Pang、Jun Wang
DOI:10.1002/chem.202001814
日期:2020.11.17
A new class of C2‐symmetric, chiral cyclopentadienyl ligand based on planar chiral ferrocene backbone was developed. A series of its corresponding rhodium(I), iridium(I), and ruthenium(II) complexes were prepared as well. In addition, the rhodium(I) complexes were evaluated in the asymmetric catalytic intramolecular amidoarylation of olefin‐tethered benzamides via C−H activation.
Rh(iii)-Catalyzed intramolecular redox-neutral cyclization of alkenes via C–H activation
作者:Zhuangzhi Shi、Mélissa Boultadakis-Arapinis、Dennis C. Koester、Frank Glorius
DOI:10.1039/c4cc00029c
日期:——
Biologically interesting fused oligocyclic lactams have been prepared via an intramolecular redox-neutral cyclization process. By the proper choice of the substrates with a wide variety of tethered olefins, the less favored CâH bond can be activated and functionalized. This CâH activation proceeds under mild conditions, obviates the need for external oxidants, and displays a broad scope with respect to the substituents.
[EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL
申请人:BLUE OAK PHARMACEUTICALS INC
公开号:WO2022204150A1
公开(公告)日:2022-09-29
The present disclosure provides compounds and pharmaceutical compositions thereof. Methods of making and using the compounds are also provided. The compounds can be used to modulate such as activate TAAR1 and can be used for the treatment, prevention, diagnosis and/or management of various CNS disorders.